Aldeyra Therapeutics (ALDX) Net Cash Flow (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Net Cash Flow of -$5.0 million for Q1 2026, down 147.09% on a QoQ basis from $10.7 million in Q4 2025, and down 20.65% year-over-year from -$6.4 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Net Cash Flow (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Net Cash Flow history runs 14 years deep, the most recent figure standing at -$5.0 million for Q1 2026.
- Quarterly Net Cash Flow fell 20.65% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (up 128.1% YoY) and the FY2025 annual result came in at $15.5 million, up 117.57% from the prior year.
- Net Cash Flow was -$5.0 million for Q1 2026 at Aldeyra Therapeutics, down from $10.7 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $20.6 million in Q1 2023 and bottomed at -$70.9 million in Q1 2022.
- A 5-year average of -$9.7 million and a median of -$5.0 million in 2026 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow slumped 2555.53% — and 2025, when it surged 722.04%.
- Aldeyra Therapeutics' Net Cash Flow stood at $15.8 million in 2022, then slumped by 103.25% to -$511872.0 in 2023, then slumped by 2555.53% to -$13.6 million in 2024, then jumped by 178.72% to $10.7 million in 2025, then tumbled by 147.09% to -$5.0 million in 2026.
- Business Quant data shows ALDX's Net Cash Flow at -$5.0 million in Q1 2026, $10.7 million in Q4 2025, and $18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 224.46 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 57.19 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | -5.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.04 Mn |
| Mar 31, 2026 | -5.04 Mn |
| Dec 31, 2025 | 10.70 Mn |
| Dec 31, 2025 | 10.70 Mn |
| Sep 30, 2025 | 18.10 Mn |
| Sep 30, 2025 | 18.10 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Mar 31, 2025 | -4.18 Mn |
| Mar 31, 2025 | -4.18 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Sep 30, 2024 | -2.91 Mn |
| Sep 30, 2024 | -2.91 Mn |
| Jun 30, 2024 | -31.46 Mn |
| Jun 30, 2024 | -31.46 Mn |
| Mar 31, 2024 | -40.33 Mn |
| Mar 31, 2024 | -40.33 Mn |
| Dec 31, 2023 | -511,872.00 |
| Dec 31, 2023 | -511,872.00 |